Genetic Testing for Psychiatric Medications: Is It Worth It?

If you have been through multiple antidepressants and none of them worked the way you expected, or if one produced side effects that seemed disproportionate to the dose, you may have wondered whether your biology is part of the reason. It might be.

Pharmacogenomic testing answers a specific question: does your genetic profile affect how your body processes certain psychiatric medications? The answer, for a meaningful subset of patients, is yes. The clinical follow-up question, whether knowing that changes your outcomes, is more complicated.

What This Page Covers

• What pharmacogenomic testing actually measures
• Which genes matter most for psychiatric medications
• What the clinical evidence says about effectiveness
• Who the evidence is strongest for
• What the APA and FDA say
• What the test cannot tell you
• How to think about whether testing makes sense for your situation

What Pharmacogenomic Testing Measures

Your liver processes most medications through a family of enzymes called cytochrome P450 enzymes. Genetic variants in the genes that encode these enzymes affect how quickly you metabolize drugs. The four most clinically important for psychiatric medications are CYP2D6, CYP2C19, CYP3A4, and CYP1A2.

These four cytochrome P450 enzymes break down more than three-quarters of psychotropic medications. CYP2D6 is especially critical because it plays a primary role in the metabolism of the most commonly prescribed psychotropics, including many antidepressants, antipsychotics, and psychostimulants.

Based on your genetic variants, you will be classified as one of four metabolizer types for each enzyme:

Poor metabolizer: missing or reduced enzyme function. Medications pile up in your system at standard doses. You face higher risk of side effects and toxicity.

Intermediate metabolizer: reduced but not absent enzyme function. Some increased medication levels at standard doses.

Normal (extensive) metabolizer: typical enzyme function. Standard dosing guidance applies.

Ultrarapid metabolizer: overactive enzyme. Medications are cleared too quickly. You may not reach therapeutic levels at standard doses.

Commercial tests such as GeneSight analyze a panel of genes and provide color-coded guidance: green (use as directed), yellow (moderate gene-drug interaction), red (significant gene-drug interaction). Pharmacogenomics identifies potential genetically related issues with medications; it does not identify medications that will work.

What the Clinical Evidence Shows

The evidence for PGx-guided prescribing in psychiatry is genuinely mixed, and being honest about that matters.

The APA Position (2023)

The American Psychiatric Association updated its analysis in 2023, reviewing 11 new clinical trials and five meta-analyses. The conclusion: evidence does not support the use of currently available combinatorial PGx tools for treatment selection in major depressive disorder. Only three of the 11 trials demonstrated efficacy on the primary outcome with statistical significance, and each used different PGx tools.

This is an important anchor for any discussion of PGx testing: the organization representing US psychiatrists has concluded that, as of 2023, routine use of combinatorial testing for first-line antidepressant selection is not supported by the available RCT evidence.

Where the Evidence Is Stronger

The picture looks better in more specific contexts.

The strongest evidence for PGx testing in psychiatry involves patients with depression who have been treated with antidepressants and who have failed to respond to at least one or more antidepressant trials. This is the subpopulation that has driven the most encouraging results, and it is also the population Medicare covers.

For specific gene-drug pairs, the evidence is solid: Poor or ultrarapid CYP2C19 metabolizers were three times more likely to stop taking escitalopram within one year compared to normal metabolizers. This is a measurable, clinically relevant finding.

Individuals who are poor or ultrarapid metabolizers of CYP2D6 and were on CYP2D6-dependent medications spent between $4,000 and $6,000 more in a one-year period compared to those with normal CYP2D6 function. The economic implications of undetected metabolizer status are real.

Recent Real-World Evidence

A 2025 real-world study in the Journal of Clinical Psychopharmacology analyzed data from over 20,000 adults with MDD who underwent PGx testing. After PGx testing, patients with MDD had decreased prescribing of medications with significant gene-drug interactions and reduced healthcare resource utilization, including significant reductions in psychiatric hospitalizations and emergency department visits.

Results are also in line with the PREPARE trial, which demonstrated a 40% reduction in psychiatric clinic hospitalizations following PGx-guided treatment in patients with MDD, schizophrenia, and bipolar disorder.

A 2024 Frontiers in Psychiatry umbrella review and updated meta-analysis found meaningful improvements in response and remission rates with PGx-guided prescribing for antidepressants, though the authors noted methodological limitations in the underlying studies.

Why the RCT Evidence Lags Real-World Evidence

The gap between RCT findings and real-world data is worth understanding. RCTs for PGx tools face a fundamental blinding problem: it is difficult to fully blind clinicians to whether they have PGx information. This introduces performance bias that can inflate the treatment-as-usual arm’s results. Additionally, most pivotal trials were conducted in predominantly female, white populations, which limits what the findings tell us about real-world populations.

What the FDA Recognizes

The FDA maintains a table of pharmacogenetic associations that documents gene-drug interactions with established clinical evidence. According to the FDA, 13 antidepressants have sufficient pharmacogenomic evidence to warrant changes to therapy. These medications are metabolized by the enzymes CYP2D6 or CYP2C19. Commercial PGx panels typically evaluate more medications than have FDA-recognized gene-drug interactions.

This is a meaningful distinction. Commercially available tests often evaluate 50 or more medications and 10 or more genes. The evidence supporting gene-drug interactions varies significantly across medications. Some interactions have strong, replicated evidence. Others are included on commercial panels based on weaker evidence or theoretical pharmacokinetic reasoning.

Who the Evidence Best Supports

If you are considering PGx testing, the evidence is most directly applicable if:

You have depression and have not responded to at least one antidepressant trial. This is the patient population with the most RCT evidence, the strongest signal in real-world data, and the one Medicare covers.

You have experienced unexpected side effects at standard doses. If a medication produced side effects that seemed disproportionate, metabolizer status is a reasonable hypothesis to investigate.

You are on multiple psychiatric medications that share metabolic pathways. Drug-drug interactions at the enzyme level can compound the effects of individual genetic variants. A CYP2D6 inhibitor combined with a CYP2D6 slow-metabolizer genotype creates additive risk.

You are about to start a medication with a known, well-validated gene-drug interaction (such as escitalopram or citalopram in the context of CYP2C19).

If you are starting treatment for the first time with no prior medication history, the evidence does not currently support PGx testing as the default first step. Your prescriber’s clinical judgment based on your symptoms, history, and preferences remains the primary driver.

What the Test Cannot Tell You

This is where many patients are let down by marketing language. A pharmacogenomic test does not help provide a diagnosis. Additionally, these tests will not tell you whether a medication is absolutely the best one for you, or the single best option for you. They may not always identify medications you should avoid.

PGx tests do not account for:

Drug-drug interactions with non-psychiatric medications. Many common drugs inhibit or induce CYP450 enzymes, effectively changing your functional metabolizer status.

Diet. Grapefruit, cruciferous vegetables, and other foods affect CYP3A4 and other enzymes.

Age. Enzyme activity changes with age and can vary significantly in older adults.

Psychodynamic factors and the therapeutic relationship. These remain significant predictors of treatment outcomes in psychiatry that no genetic test addresses.

The specific biology of your depression or anxiety. PGx testing captures metabolic genetics, not the full neurobiological landscape of your condition.

What It Does Right

Despite these limitations, PGx testing fills a genuine clinical gap. It is a once-in-a-lifetime test that can be very useful. Your genetics don’t change, so results obtained now inform prescribing decisions indefinitely.

In an electronic health record analysis of nearly 3,400 psychiatric PGx test recipients from a multi-clinic health system, 95% had at least one clinically actionable PGx variant relevant to psychiatric and non-psychiatric prescribing. Most people who get tested get information that is relevant to their clinical care.

For patients who have been through multiple medication trials and are weighing options, PGx data adds a layer of specificity. It can inform whether a medication that appears equivalent on clinical grounds has a genetic reason to avoid it. It can explain a prior adverse reaction. It can shift the conversation from trial-and-error to evidence-informed selection.

What This Means for Your Care

If you are exploring PGx testing, several practical points:

Talk to your prescriber before ordering. A PGx result in the wrong hands, or without clinical context, can lead to suboptimal decisions. The FDA and professional societies emphasize that PGx results should be one input among many, not a deterministic prescription for a specific drug.

Ask specifically about coverage. If you have Medicare and have failed at least one antidepressant, you may have coverage. Commercial coverage varies by plan and clinical indication.

Store the results. If you get tested, make sure the results are documented in your medical record and accessible to any future prescriber.

Do not let the result overrule your clinical experience. If a medication has worked well for you, a yellow flag on a PGx test is not a reason to stop it. If a medication caused significant problems, a green flag does not mean it was safe for you specifically.

“I use pharmacogenomic data as one piece of the clinical picture, particularly when a patient has had unexplained responses or side effects to multiple medications,” says Daniel Montville, MD, Psychiatrist, of the SiggyMD clinical team. “It is not a decision-maker. But for someone who has been on five antidepressants without a clear success, it gives me a more specific conversation to have about what we try next.”

What Members Are Saying

JD

J.D., 43

Major Depressive Disorder

“I had been on four antidepressants. All of them either didn’t work or produced side effects that were worse than the depression. When my new psychiatrist ordered genetic testing, it turned out I metabolize CYP2D6 poorly. Two of my previous medications had significant gene-drug interactions flagged in the results. We chose a medication outside those pathways and it’s working. That information changed the conversation.”

AS

A.S., 29

Anxiety and Depression, First Treatment

“My prescriber explained the test was most useful if my first medication didn’t work. We decided to try standard first-line treatment first and consider testing if that didn’t go well. It didn’t have to come to that. The first medication worked. But I appreciated that the decision about when to use testing was made based on evidence rather than just ordering it up front.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

The Bottom Line

Pharmacogenomic testing for psychiatric medications is real science, not marketing. The gene-drug interactions it identifies, particularly CYP2D6 and CYP2C19 variants and specific antidepressants, are well-validated and clinically meaningful.

The evidence is most robust for patients who have already failed at least one antidepressant trial. The APA does not support routine first-line use. Real-world data from large patient populations is increasingly positive, and the quality of studies is improving.

PGx testing is a tool that adds specificity to a clinical conversation, not a replacement for clinical judgment. If you have been through multiple medication trials without finding something that works well, it is worth raising with your prescriber.

For a broader look at how antidepressants differ and what influences medication selection, read about how prescribers decide between first- and second-line antidepressants. Or start your anonymous intake with SiggyMD to connect with a licensed prescriber who can review your medication history and discuss whether pharmacogenomic testing is appropriate for your situation.

Sources

1. Muller DJ, et al. Pharmacogenomic Testing May Help Achieve Better Patient Outcomes, Reduced Toxicity. Psychiatric News. 2022.

2. Perlis RH, et al. Pharmacogenomic Clinical Support Tools for the Treatment of Depression. American Journal of Psychiatry. 2023;180(9):640-645.

3. Del Tredici AL, et al. Real-World Impact of Pharmacogenomic Testing on Medication Use and Healthcare Resource Utilization in Patients with Major Depressive Disorder. Journal of Clinical Psychopharmacology. 2025.

4. Tesfamicael KG, et al. Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis. Frontiers in Psychiatry. 2024;15:1276410.

5. Zhang L, et al. Real-World Characterization of Psychiatric Pharmacogenomic Test Ordering and Clinical Relevance in Adults and Children. Clinical and Translational Science. 2025;18:e70297.

6. NAMI. Pharmacogenomic Testing. Accessed June 2026.

7. Bishop JR, et al. Pharmacogenomics to support mental health medication therapy management. JACCP. 2024;7(2):160-170.

8. NCBI Bookshelf. An Overview of Pharmacogenomic Testing for Psychiatric Disorders. 2023.

9. Altar CA, et al. Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy. Molecular Neuropsychiatry. 2015;1:145-155.

10. AAFP. GeneSight Psychotropic Genetic Testing for Psychiatric Medication Selection. American Family Physician. 2021;104(1):89-90.